Abatacept

BNF:: 10.1.3
Status:: Do Not Prescribe (DNP), Red
Decision Date:: May 2013

Comments

RED:

NICE TA373 for treating juvenile idiopathic arthritis (JIA). NHSE commissioned. (Decision date - January 2016)
NICE TA375*: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Replaces TA280) (Decision date - February 2016)

*Local agreement for abatacept use as monotherapy for patients with severe RA and interstitial lung disease. (Decision date - February 2022)

For severe treatment-resistant morphoea (localised scleroderma) (adults and children 2 years and over). NHSE commissioned (Decision date - September 2021)
Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 and over). NHSE commissioned. (Decision date - February 2022

DO NOT PRESCRIBE (DNP)

NICE TA568: for treating psoriatic arthritis after DMARDS. (Terminated appraisal) (Decision date -April 2019)
NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

Black Drug Classifications

6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)